share_log

Cantor Fitzgerald Reiterates Overweight on 4D Molecular Therapeutics

Benzinga ·  Sep 10 01:03

Cantor Fitzgerald analyst Josh Schimmer reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment